Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Network, transcriptomic and genomic features differentiate genes relevant for drug response

  • Piñero González, Janet, 1977-
  • Gonzalez-Perez, Abel
  • Guney, Emre
  • Aguirre Plans, Joaquim, 1993-
  • Sanz, Ferran
  • Oliva Miguel, Baldomero
  • Furlong, Laura I., 1971-
Understanding the mechanisms underlying drug therapeutic action and toxicity is crucial for the prevention and management of drug adverse reactions, and paves the way for a more efficient and rational drug design. The characterization of drug targets, drug metabolism proteins, and proteins associated to side effects according to their expression patterns, their tolerance to genomic variation and their role in cellular networks, is a necessary step in this direction. In this contribution, we hypothesize that different classes of proteins involved in the therapeutic effect of drugs and in their adverse effects have distinctive transcriptomics, genomics and network features. We explored the properties of these proteins within global and organ-specific interactomes, using multi-scale network features, evaluated their gene expression profiles in different organs and tissues, and assessed their tolerance to loss-of-function variants leveraging data from 60K subjects. We found that drug targets that mediate side effects are more central in cellular networks, more intolerant to loss-of-function variation, and show a wider breadth of tissue expression than targets not mediating side effects. In contrast, drug metabolizing enzymes and transporters are less central in the interactome, more tolerant to deleterious variants, and are more constrained in their tissue expression pattern. Our findings highlight distinctive features of proteins related to drug action, which could be applied to prioritize drugs with fewer probabilities of causing side effects., We received support from ISCIII-FEDER (PI13/00082, CP10/00524, and CPII16/00026), IMI-JU under grant agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE) resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Program 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and was supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370). AG-P was supported by a Ramón y Cajal contract (RYC-2013-14554). BO and JA-P were supported by MINECO grant BIO2014-57518-R.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GUILDify v2.0: a tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
  • Guney, Emre
The genetic basis of complex diseases involves alterations on multiple genes. Unraveling the interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 2014, we introduced GUILDify, a web server that searches for genes associated to diseases, finds novel disease genes applying various network-based prioritization algorithms and proposes candidate drugs. Here, we present GUILDify v2.0, a major update and improvement of the original method, where we have included protein interaction data for seven species and 22 human tissues and incorporated the disease-gene associations from DisGeNET. To infer potential disease relationships associated with multi-morbidities, we introduced a novel feature for estimating the genetic and functional overlap of two diseases using the top-ranking genes and the associated enrichment of biological functions and pathways (as defined by GO and Reactome). The analysis of this overlap helps to identify the mechanistic role of genes and protein-protein interactions in comorbidities. Finally, we provided an R package, guildifyR, to facilitate programmatic access to GUILDify v2.0 (http://sbi.upf.edu/guildify2)., The authors received support from the following:ISCIII–FEDER (PI13/00082, CP10/00524, CPII16/00026); IMI-JU under grants agreements no. 116030(TransQST) and no. 777365 (eTRANSAFE), re-sources of which are composed of financial contribu-tion from the EU-FP7 (FP7/2007- 2013) and EFPIAcompanies in kind contribution; the EU H2020Programme 2014–2020 under grant agreementsno. 634143 (MedBioinformatics) and no. 676559(Elixir-Excelerate); the Spanish Ministry of Economy(MINECO) (BIO2017-85329-R, RYC-2015-17519);and“Unidad de Excelencia María de Maeztu,”fundedby the Spanish Ministry of Economy (ref.: MDM-2014-0370). The Research Programme on BiomedicalInformatics is a member of the Spanish NationalBioinformatics Institute, PRB2-ISCIII, and is supportedby Grant PT13/0001/0023 of the PE I+D+i 2013-2016funded by ISCIII and FEDER
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Menche, Jörg
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Schmidt, Harald H.H.W.
  • Oliva Miguel, Baldomero
  • Guney, Emre
The past decades have witnessed a paradigm shift from the traditional drug discovery shaped around the idea of "one target, one disease" to polypharmacology (multiple targets, one disease). Given the lack of clear-cut boundaries across disease (endo)phenotypes and genetic heterogeneity across patients, a natural extension to the current polypharmacology paradigm is to target common biological pathways involved in diseases via endopharmacology (multiple targets, multiple diseases). In this study, we present proximal pathway enrichment analysis (PxEA) for pinpointing drugs that target common disease pathways towards network endopharmacology. PxEA uses the topology information of the network of interactions between disease genes, pathway genes, drug targets and other proteins to rank drugs by their interactome-based proximity to pathways shared across multiple diseases, providing unprecedented drug repurposing opportunities. Using PxEA, we show that many drugs indicated for autoimmune disorders are not necessarily specific to the condition of interest, but rather target the common biological pathways across these diseases. Finally, we provide high scoring drug repurposing candidates that can target common mechanisms involved in type 2 diabetes and Alzheimer's disease, two conditions that have recently gained attention due to the increased comorbidity among patients., The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The authors also received support from EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate). E.G. was supported by EU-cofunded Beatriu de Pinós incoming fellowship from the Agency for Management of University and Research Grants (AGAUR) of Government of Catalunya and L.I.F. received support from ISCIII-FEDER (CPII16/00026). H.H.H.W.S. has received funding from from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777111 (Repotrial). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Benchmarking post-GWAS analysis tools in major depression: Challenges and implications

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
Our knowledge of complex disorders has increased in the last years thanks to the identification of genetic variants (GVs) significantly associated with disease phenotypes by genome-wide association studies (GWAS). However, we do not understand yet how these GVs functionally impact disease pathogenesis or their underlying biological mechanisms. Among the multiple post-GWAS methods available, fine-mapping and colocalization approaches are commonly used to identify causal GVs, meaning those with a biological effect on the trait, and their functional effects. Despite the variety of post-GWAS tools available, there is no guideline for method eligibility or validity, even though these methods work under different assumptions when accounting for linkage disequilibrium and integrating molecular annotation data. Moreover, there is no benchmarking of the available tools. In this context, we have applied two different fine-mapping and colocalization methods to the same GWAS on major depression (MD) and expression quantitative trait loci (eQTL) datasets. Our goal is to perform a systematic comparison of the results obtained by the different tools. To that end, we have evaluated their results at different levels: fine-mapped and colocalizing GVs, their target genes and tissue specificity according to gene expression information, as well as the biological processes in which they are involved. Our findings highlight the importance of fine-mapping as a key step for subsequent analysis. Notably, the colocalizing variants, altered genes and targeted tissues differed between methods, even regarding their biological implications. This contribution illustrates an important issue in post-GWAS analysis with relevant consequences on the use of GWAS results for elucidation of disease pathobiology, drug target prioritization and biomarker discovery., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA (GA: 116030 TransQST and GA: 777365 eTRANSAFE), and the EU H2020 Programme 2014–2020 (GA: 676559 Elixir-Excelerate); Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya (2017SGR00519), and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII (PT13/0001/0023, of the PE I + D + i 2013–2016)). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (MDM-2014-0370). JP-G was supported by Instituto de Salud Carlos III-Fondo Social Europeo (FI18/00034). This statement is a requirement from our funding agencies and therefore has to be included in the Funding section.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Embracing the dark side: computational approaches to unveil the functionality of genes lacking biological annotation in drug-induced liver injury

  • Souza, Terezinha
  • Panuwat, Trairatphisan
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • Saez-Rodriguez, Julio
  • Kleinjans, Jos C.
  • Jennen, Danyel
In toxicogenomics, functional annotation is an important step to gain additional insights into genes with aberrant expression that drive pathophysiological mechanisms. Nevertheless, there exists a gap on annotation of these genes which often hampers the interpretation of results and limits their applicability in translational medicine. In this study, we evaluated the coverage of functional annotations of differentially expressed genes (DEGs) induced by 10 selected compounds from the TG-GATEs database identified as high- or no-risk in causing drug-induced liver injury (most-DILI or no-DILI, respectively) using in vitro human data. Functional roles of DEGs not present in the most common biological annotation databases - termed "dark genes" - were unveiled via literature mining and via the identification of shared regulatory transcription factors or signaling pathways. Our results demonstrated that there were approximately 13% of dark genes induced by these compounds in vitro and we were able to obtain additional relevant information for up to 76% of those. Using interactome data from several sources, we have uncovered genes such as LRBA, and WDR26 as highly connected in the protein network that play roles in drug response. Genes such as MALAT1, H19, and MIR29C - whose links to hepatotoxicity have been confirmed - were identified as markers for the most-DILI group and appeared as top hits across all literature-based mining methods. Furthermore, we investigated the potential impact of dark genes on liver toxicity by identifying their rat orthologs in combination with their correlation to drug-induced liver pathologies observed in vivo following chemical exposure. We identified a set of important regulatory transcription factors of dark genes for all most-DILI compounds including E2F1 and JUND with supporting evidences in literature and we found Magee1 correlated with chemically induced bile duct hyperplasia and adverse responses at 29 days in rats in vivo. In conclusion, in this study we show the potential role of these poorly annotated genes in mechanisms underlying hepatotoxicity and offer a number of computational approaches that may help to minimize current gaps in gene annotation and highlight their values as potential biomarkers in toxicological studies., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116030 (TransQST). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The DisGeNET knowledge platform for disease genomics: 2019 update

  • Piñero González, Janet, 1977-
  • Ramírez Anguita, Juan Manuel
  • Saüch Pitarch, Josep
  • Ronzano, Francesco
  • Centeno, Emilio
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
One of the most pressing challenges in genomic medicine is to understand the role played by genetic variation in health and disease. Thanks to the exploration of genomic variants at large scale, hundreds of thousands of disease-associated loci have been uncovered. However, the identification of variants of clinical relevance is a significant challenge that requires comprehensive interrogation of previous knowledge and linkage to new experimental results. To assist in this complex task, we created DisGeNET (http://www.disgenet.org/), a knowledge management platform integrating and standardizing data about disease associated genes and variants from multiple sources, including the scientific literature. DisGeNET covers the full spectrum of human diseases as well as normal and abnormal traits. The current release covers more than 24 000 diseases and traits, 17 000 genes and 117 000 genomic variants. The latest developments of DisGeNET include new sources of data, novel data attributes and prioritization metrics, a redesigned web interface and recently launched APIs. Thanks to the data standardization, the combination of expert curated information with data automatically mined from the scientific literature, and a suite of tools for accessing its publicly available data, DisGeNET is an interoperable resource supporting a variety of applications in genomic medicine and drug R&D., SCIII-FEDER [PI13/00082, PI17/00230, CPII16/00026]; IMI-JU resources of which are composed of financial contribution from the EU-FP7 [FP7/2007–2013] and EFPIA companies in kind contribution [116030 to TransQST, 777365 to eTRANSAFE], and the EU H2020 Programme 2014–2020 [676559 to Elixir-Excelerate]; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PRB2-ISCIII [PT13/0001/0023, of the PE I+D+i 2013–2016]). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. Funding for open access charge: Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity

  • Gall, Louis
  • Jardí Pujol, Ferran
  • Lammens, Lieve
  • Piñero González, Janet, 1977-
  • Souza, Terezinha
  • Rodrigues, Daniela
  • Jennen, Danyel
  • de Kok, Theo M.
  • Coyle, Luke
  • Chung, Seung-Wook
  • Ferreira, Sofia
  • Jo, Heeseung
  • Beattie, Kylie A.
  • Kelly, Colette
  • Duckworth, Carrie A.
  • Pritchard, Mark
  • Pin, Carmen
We have built a quantitative systems toxicology modeling framework focused on the early prediction of oncotherapeutic-induced clinical intestinal adverse effects. The model describes stem and progenitor cell dynamics in the small intestinal epithelium and integrates heterogeneous epithelial-related processes, such as transcriptional profiles, citrulline kinetics, and probability of diarrhea. We fitted a mouse-specific version of the model to quantify doxorubicin and 5-fluorouracil (5-FU)-induced toxicity, which included pharmacokinetics and 5-FU metabolism and assumed that both drugs led to cell cycle arrest and apoptosis in stem cells and proliferative progenitors. The model successfully recapitulated observations in mice regarding dose-dependent disruption of proliferation which could lead to villus shortening, decrease of circulating citrulline, increased diarrhea risk, and transcriptional induction of the p53 pathway. Using a human-specific epithelial model, we translated the cytotoxic activity of doxorubicin and 5-FU quantified in mice into human intestinal injury and predicted with accuracy clinical diarrhea incidence. However, for gefitinib, a specific-molecularly targeted therapy, the mice failed to reproduce epithelial toxicity at exposures much higher than those associated with clinical diarrhea. This indicates that, regardless of the translational modeling approach, preclinical experimental settings have to be suitable to quantify drug-induced clinical toxicity with precision at the structural scale of the model. Our work demonstrates the usefulness of translational models at early stages of the drug development pipeline to predict clinical toxicity and highlights the importance of understanding cross-settings differences in toxicity when building these approaches., The authors acknowledge financial support from TransQST consortium. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Flame: an open source framework for model development, hosting, and usage in production environments

  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Sanz, Ferran
This article describes Flame, an open source software for building predictive models and supporting their use in production environments. Flame is a web application with a web-based graphic interface, which can be used as a desktop application or installed in a server receiving requests from multiple users. Models can be built starting from any collection of biologically annotated chemical structures since the software supports structural normalization, molecular descriptor calculation, and machine learning model generation using predefined workflows. The model building workflow can be customized from the graphic interface, selecting the type of normalization, molecular descriptors, and machine learning algorithm to be used from a panel of state-of-the-art methods implemented natively. Moreover, Flame implements a mechanism allowing to extend its source code, adding unlimited model customization. Models generated with Flame can be easily exported, facilitating collaborative model development. All models are stored in a model repository supporting model versioning. Models are identified by unique model IDs and include detailed documentation formatted using widely accepted standards. The current version is the result of nearly 3 years of development in collaboration with users from the pharmaceutical industry within the IMI eTRANSAFE project, which aims, among other objectives, to develop high-quality predictive models based on shared legacy data for assessing the safety of drug candidates., This work has received funding from the eTRANSAFE project (Grant Agreement No. 777365), developed under the Innovative Medicines Initiative Joint Undertaking (IMI2), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects which contributed funding, such as TransQST (No. 116030) as well as the H2020 EU-ToxRisk project (No. 681002) and FAIRplus (No. 802750). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Functional genomics analysis to disentangle the role of genetic variants in major depression

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Medina-Rivera, Alejandra
  • Furlong, Laura I., 1971-
Understanding the molecular basis of major depression is critical for identifying new potential biomarkers and drug targets to alleviate its burden on society. Leveraging available GWAS data and functional genomic tools to assess regulatory variation could help explain the role of major depression-associated genetic variants in disease pathogenesis. We have conducted a fine-mapping analysis of genetic variants associated with major depression and applied a pipeline focused on gene expression regulation by using two complementary approaches: cis-eQTL colocalization analysis and alteration of transcription factor binding sites. The fine-mapping process uncovered putative causally associated variants whose proximal genes were linked with major depression pathophysiology. Four colocalizing genetic variants altered the expression of five genes, highlighting the role of SLC12A5 in neuronal chlorine homeostasis and MYRF in nervous system myelination and oligodendrocyte differentiation. The transcription factor binding analysis revealed the potential role of rs62259947 in modulating P4HTM expression by altering the YY1 binding site, altogether regulating hypoxia response. Overall, our pipeline could prioritize putative causal genetic variants in major depression. More importantly, it can be applied when only index genetic variants are available. Finally, the presented approach enabled the proposal of mechanistic hypotheses of these genetic variants and their role in disease pathogenesis., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme 2014–2020 [GA: 676559 Elixir-Excelerate]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013–2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. AMR was supported by CONACYT-FORDECYT-PRONACES grant no. [11311], and Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México (PAPIIT-UNAM) grant nos. IA203021. JPG was supported by Instituto de Salud Carlos III-Fondo Social Europeo [FI18/00034]; Instituto de Salud Carlos III [MV20]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX Project

  • Pastor Maeso, Manuel
  • Quintana, Jordi
  • Sanz, Ferran
In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future., The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set

  • Del Toro, N.
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • Porras, P.
  • IMEx Consortium Curators
The current wealth of genomic variation data identified at nucleotide level presents the challenge of understanding by which mechanisms amino acid variation affects cellular processes. These effects may manifest as distinct phenotypic differences between individuals or result in the development of disease. Physical interactions between molecules are the linking steps underlying most, if not all, cellular processes. Understanding the effects that sequence variation has on a molecule's interactions is a key step towards connecting mechanistic characterization of nonsynonymous variation to phenotype. We present an open access resource created over 14 years by IMEx database curators, featuring 28,000 annotations describing the effect of small sequence changes on physical protein interactions. We describe how this resource was built, the formats in which the data is provided and offer a descriptive analysis of the data set. The data set is publicly available through the IntAct website and is enhanced with every monthly release., The IntAct database and EMBL-EBI-based authors received funding from EMBL core funding and Open Targets (grant agreement OTAR-044). The DIP database is funded by NIH grant R01GM123126. MINT received support from ERC grant ‘DEPTH project of the European Research Council (grant agreement 322749)’. The British Heart Foundation-University College of London (BHF-UCL) curation team is funded with the British Heart Foundation grant RG/13/5/30112. UniProt curation activities at EMBL-EBI and the Swiss Institute of Bioinformatics are funded by the National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, and National Institute of Mental Health of the National Institutes of Health under Award Number [U24HG007822], National Human Genome Research Institute under Award Numbers [U41HG007822 and U41HG002273], and the National Institute of General Medical Sciences under Award Numbers [R01GM080646, P20GM103446 and U01GM120953] (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health); Swiss Federal Government through the State Secretariat for Education, Research and Innovation; and aforementioned British Heart Foundation grants and EMBL core funding. DisGeNET is supported with EU-FP7 funds from ISCIII-FEDER (CP10/00524, CPII16/00026), IMI-JU (grant agreement no. 116030, TransQST) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014-2020 (grant agreements no. 634143, MedBioinformatics and no. 676559, Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (ref: MDM-2014-0370). I.J. and group supported in part by Krembil Foundation, Ontario Research Fund (#34876), and Canada Foundation for Innovation (CFI #225404, #30865, #33536). The authors would like to thank Marco Galardini, Luz García-Alonso, Denes Turei and Martin Krallinger for valuable discussions when designing the data set output format; Iain Moal for providing key information about SKEMPI 2.0; Danish Memon for his help pre-processing cBioPortal data; and Luz García-Alonso as the creator of the Python scripts we used to parse UniProt mutagenesis annotations.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Parallel ant colony optimization for the training of cell signaling networks

  • González, Patricia
  • Prado Rodríguez, Roberto
  • Gábor, Attila
  • Sáez-Rodríguez, Julio
  • Banga, Julio R.
  • Doallo, Ramón
Acquiring a functional comprehension of the deregulation of cell signaling networks in disease allows progress in the development of new therapies and drugs. Computational models are becoming increasingly popular as a systematic tool to analyze the functioning of complex biochemical networks, such as those involved in cell signaling. CellNOpt is a framework to build predictive logic-based models of signaling pathways by training a prior knowledge network to biochemical data obtained from perturbation experiments. This training can be formulated as an optimization problem that can be solved using metaheuristics. However, the genetic algorithm used so far in CellNOpt presents limitations in terms of execution time and quality of solutions when applied to large instances. Thus, in order to overcome those issues, in this paper we propose the use of a method based on ant colony optimization, adapted to the problem at hand and parallelized using a hybrid approach. The performance of this novel method is illustrated with several challenging benchmark problems in the study of new therapies for liver cancer., This work was supported by the Ministry of Science and Innovation of Spain (PID2019-104184RB-I00/AEI/10.13039/501100011033), and by Xunta de Galicia, Spain and FEDER funds of the EU (Centro de Investigación de Galicia accreditation 2019–2022, ref. ED431G 2019/01; Consolidation Program of Competitive Reference Groups, ref. ED431C 2021/30). JRB acknowledges funding from the Ministry of Science and Innovation of Spain MCIN/AEI/10.13039/501100011033 through grant PID2020-117271RB-C22 (BIODYNAMICS). AG acknowledges funding from the European Union Innovative Medicines Initiative TransQST (agreement No.116030). Authors also acknowledge the Galician Supercomputing Center (CESGA) for the access to its facilities. Funding for open access charge: Universidade da Coruña/CISUG., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity

  • Gall, Louis
  • Jardí Pujol, Ferran
  • Lammens, Lieve
  • Piñero González, Janet, 1977-
  • Souza, Terezinha
  • Rodrigues, Daniela
  • Jennen, Danyel
  • de Kok, Theo M.
  • Coyle, Luke
  • Chung, Seung-Wook
  • Ferreira, Sofia
  • Jo, Heeseung
  • Beattie, Kylie A.
  • Kelly, Colette
  • Duckworth, Carrie A.
  • Pritchard, Mark
  • Pin, Carmen
We have built a quantitative systems toxicology modeling framework focused on the early prediction of oncotherapeutic-induced clinical intestinal adverse effects. The model describes stem and progenitor cell dynamics in the small intestinal epithelium and integrates heterogeneous epithelial-related processes, such as transcriptional profiles, citrulline kinetics, and probability of diarrhea. We fitted a mouse-specific version of the model to quantify doxorubicin and 5-fluorouracil (5-FU)-induced toxicity, which included pharmacokinetics and 5-FU metabolism and assumed that both drugs led to cell cycle arrest and apoptosis in stem cells and proliferative progenitors. The model successfully recapitulated observations in mice regarding dose-dependent disruption of proliferation which could lead to villus shortening, decrease of circulating citrulline, increased diarrhea risk, and transcriptional induction of the p53 pathway. Using a human-specific epithelial model, we translated the cytotoxic activity of doxorubicin and 5-FU quantified in mice into human intestinal injury and predicted with accuracy clinical diarrhea incidence. However, for gefitinib, a specific-molecularly targeted therapy, the mice failed to reproduce epithelial toxicity at exposures much higher than those associated with clinical diarrhea. This indicates that, regardless of the translational modeling approach, preclinical experimental settings have to be suitable to quantify drug-induced clinical toxicity with precision at the structural scale of the model. Our work demonstrates the usefulness of translational models at early stages of the drug development pipeline to predict clinical toxicity and highlights the importance of understanding cross-settings differences in toxicity when building these approaches., The authors acknowledge financial support from TransQST consortium. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX Project

  • Pastor Maeso, Manuel
  • Quintana, Jordi
  • Sanz, Ferran
In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future., The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Menche, Jörg
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Schmidt, Harald H.H.W.
  • Oliva Miguel, Baldomero
  • Guney, Emre
The past decades have witnessed a paradigm shift from the traditional drug discovery shaped around the idea of "one target, one disease" to polypharmacology (multiple targets, one disease). Given the lack of clear-cut boundaries across disease (endo)phenotypes and genetic heterogeneity across patients, a natural extension to the current polypharmacology paradigm is to target common biological pathways involved in diseases via endopharmacology (multiple targets, multiple diseases). In this study, we present proximal pathway enrichment analysis (PxEA) for pinpointing drugs that target common disease pathways towards network endopharmacology. PxEA uses the topology information of the network of interactions between disease genes, pathway genes, drug targets and other proteins to rank drugs by their interactome-based proximity to pathways shared across multiple diseases, providing unprecedented drug repurposing opportunities. Using PxEA, we show that many drugs indicated for autoimmune disorders are not necessarily specific to the condition of interest, but rather target the common biological pathways across these diseases. Finally, we provide high scoring drug repurposing candidates that can target common mechanisms involved in type 2 diabetes and Alzheimer's disease, two conditions that have recently gained attention due to the increased comorbidity among patients., The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The authors also received support from EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate). E.G. was supported by EU-cofunded Beatriu de Pinós incoming fellowship from the Agency for Management of University and Research Grants (AGAUR) of Government of Catalunya and L.I.F. received support from ISCIII-FEDER (CPII16/00026). H.H.H.W.S. has received funding from from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777111 (Repotrial). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Flame: an open source framework for model development, hosting, and usage in production environments

  • Pastor Maeso, Manuel
  • Gómez-Tamayo, José C.
  • Sanz, Ferran
This article describes Flame, an open source software for building predictive models and supporting their use in production environments. Flame is a web application with a web-based graphic interface, which can be used as a desktop application or installed in a server receiving requests from multiple users. Models can be built starting from any collection of biologically annotated chemical structures since the software supports structural normalization, molecular descriptor calculation, and machine learning model generation using predefined workflows. The model building workflow can be customized from the graphic interface, selecting the type of normalization, molecular descriptors, and machine learning algorithm to be used from a panel of state-of-the-art methods implemented natively. Moreover, Flame implements a mechanism allowing to extend its source code, adding unlimited model customization. Models generated with Flame can be easily exported, facilitating collaborative model development. All models are stored in a model repository supporting model versioning. Models are identified by unique model IDs and include detailed documentation formatted using widely accepted standards. The current version is the result of nearly 3 years of development in collaboration with users from the pharmaceutical industry within the IMI eTRANSAFE project, which aims, among other objectives, to develop high-quality predictive models based on shared legacy data for assessing the safety of drug candidates., This work has received funding from the eTRANSAFE project (Grant Agreement No. 777365), developed under the Innovative Medicines Initiative Joint Undertaking (IMI2), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects which contributed funding, such as TransQST (No. 116030) as well as the H2020 EU-ToxRisk project (No. 681002) and FAIRplus (No. 802750). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identifying multiscale translational safety biomarkers using a network-based systems approach

  • Callegaro, Giulia
  • Schimming, Johannes P.
  • Piñero González, Janet, 1977-
  • Kunnen, Steven J.
  • Wijaya, Lukas
  • Trairatphisan, Panuwat
  • van den Berk, Linda
  • Beetsma, Kim
  • Furlong, Laura I.
  • Sutherland, Jeffrey J.
  • Mollon, Jennifer
  • Stevens, James L.
  • van de Water, Bob
Animal testing is the current standard for drug and chemicals safety assessment, but hazards translation to human is uncertain. Human in vitro models can address the species translation but might not replicate in vivo complexity. Herein, we propose a network-based method addressing these translational multiscale problems that derives in vivo liver injury biomarkers applicable to in vitro human early safety screening. We applied weighted correlation network analysis (WGCNA) to a large rat liver transcriptomic dataset to obtain co-regulated gene clusters (modules). We identified modules statistically associated with liver pathologies, including a module enriched for ATF4-regulated genes as associated with the occurrence of hepatocellular single-cell necrosis, and as preserved in human liver in vitro models. Within the module, we identified TRIB3 and MTHFD2 as a novel candidate stress biomarkers, and developed and used BAC-eGFPHepG2 reporters in a compound screening, identifying compounds showing ATF4-dependent stress response and potential early safety signals., This work was supported by the EU-EFPIA Innovative Medicines Initiative 2 (IMI2) Joint Undertaking TransQST project (grant number 116030) and eTRANSAFE project (grant number 777365) (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA), the EC Horizon2020 EU-ToxRisk project (grant number 681002), the European Research & Innovation project funded under the European Commission’s Horizon 2020 program RISK-HUNT3R project (grant number 964537) and the Cosmetics Europe/CEFIC Liver Ontology project.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set

  • Del Toro, N.
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • Porras, P.
  • IMEx Consortium Curators
The current wealth of genomic variation data identified at nucleotide level presents the challenge of understanding by which mechanisms amino acid variation affects cellular processes. These effects may manifest as distinct phenotypic differences between individuals or result in the development of disease. Physical interactions between molecules are the linking steps underlying most, if not all, cellular processes. Understanding the effects that sequence variation has on a molecule's interactions is a key step towards connecting mechanistic characterization of nonsynonymous variation to phenotype. We present an open access resource created over 14 years by IMEx database curators, featuring 28,000 annotations describing the effect of small sequence changes on physical protein interactions. We describe how this resource was built, the formats in which the data is provided and offer a descriptive analysis of the data set. The data set is publicly available through the IntAct website and is enhanced with every monthly release., The IntAct database and EMBL-EBI-based authors received funding from EMBL core funding and Open Targets (grant agreement OTAR-044). The DIP database is funded by NIH grant R01GM123126. MINT received support from ERC grant ‘DEPTH project of the European Research Council (grant agreement 322749)’. The British Heart Foundation-University College of London (BHF-UCL) curation team is funded with the British Heart Foundation grant RG/13/5/30112. UniProt curation activities at EMBL-EBI and the Swiss Institute of Bioinformatics are funded by the National Eye Institute, National Human Genome Research Institute, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, and National Institute of Mental Health of the National Institutes of Health under Award Number [U24HG007822], National Human Genome Research Institute under Award Numbers [U41HG007822 and U41HG002273], and the National Institute of General Medical Sciences under Award Numbers [R01GM080646, P20GM103446 and U01GM120953] (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health); Swiss Federal Government through the State Secretariat for Education, Research and Innovation; and aforementioned British Heart Foundation grants and EMBL core funding. DisGeNET is supported with EU-FP7 funds from ISCIII-FEDER (CP10/00524, CPII16/00026), IMI-JU (grant agreement no. 116030, TransQST) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014-2020 (grant agreements no. 634143, MedBioinformatics and no. 676559, Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (ref: MDM-2014-0370). I.J. and group supported in part by Krembil Foundation, Ontario Research Fund (#34876), and Canada Foundation for Innovation (CFI #225404, #30865, #33536). The authors would like to thank Marco Galardini, Luz García-Alonso, Denes Turei and Martin Krallinger for valuable discussions when designing the data set output format; Iain Moal for providing key information about SKEMPI 2.0; Danish Memon for his help pre-processing cBioPortal data; and Luz García-Alonso as the creator of the Python scripts we used to parse UniProt mutagenesis annotations.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Benchmarking post-GWAS analysis tools in major depression: Challenges and implications

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
Our knowledge of complex disorders has increased in the last years thanks to the identification of genetic variants (GVs) significantly associated with disease phenotypes by genome-wide association studies (GWAS). However, we do not understand yet how these GVs functionally impact disease pathogenesis or their underlying biological mechanisms. Among the multiple post-GWAS methods available, fine-mapping and colocalization approaches are commonly used to identify causal GVs, meaning those with a biological effect on the trait, and their functional effects. Despite the variety of post-GWAS tools available, there is no guideline for method eligibility or validity, even though these methods work under different assumptions when accounting for linkage disequilibrium and integrating molecular annotation data. Moreover, there is no benchmarking of the available tools. In this context, we have applied two different fine-mapping and colocalization methods to the same GWAS on major depression (MD) and expression quantitative trait loci (eQTL) datasets. Our goal is to perform a systematic comparison of the results obtained by the different tools. To that end, we have evaluated their results at different levels: fine-mapped and colocalizing GVs, their target genes and tissue specificity according to gene expression information, as well as the biological processes in which they are involved. Our findings highlight the importance of fine-mapping as a key step for subsequent analysis. Notably, the colocalizing variants, altered genes and targeted tissues differed between methods, even regarding their biological implications. This contribution illustrates an important issue in post-GWAS analysis with relevant consequences on the use of GWAS results for elucidation of disease pathobiology, drug target prioritization and biomarker discovery., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA (GA: 116030 TransQST and GA: 777365 eTRANSAFE), and the EU H2020 Programme 2014–2020 (GA: 676559 Elixir-Excelerate); Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya (2017SGR00519), and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII (PT13/0001/0023, of the PE I + D + i 2013–2016)). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (MDM-2014-0370). JP-G was supported by Instituto de Salud Carlos III-Fondo Social Europeo (FI18/00034). This statement is a requirement from our funding agencies and therefore has to be included in the Funding section.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Functional genomics analysis to disentangle the role of genetic variants in major depression

  • Pérez-Granado, Judith
  • Piñero González, Janet, 1977-
  • Medina-Rivera, Alejandra
  • Furlong, Laura I., 1971-
Understanding the molecular basis of major depression is critical for identifying new potential biomarkers and drug targets to alleviate its burden on society. Leveraging available GWAS data and functional genomic tools to assess regulatory variation could help explain the role of major depression-associated genetic variants in disease pathogenesis. We have conducted a fine-mapping analysis of genetic variants associated with major depression and applied a pipeline focused on gene expression regulation by using two complementary approaches: cis-eQTL colocalization analysis and alteration of transcription factor binding sites. The fine-mapping process uncovered putative causally associated variants whose proximal genes were linked with major depression pathophysiology. Four colocalizing genetic variants altered the expression of five genes, highlighting the role of SLC12A5 in neuronal chlorine homeostasis and MYRF in nervous system myelination and oligodendrocyte differentiation. The transcription factor binding analysis revealed the potential role of rs62259947 in modulating P4HTM expression by altering the YY1 binding site, altogether regulating hypoxia response. Overall, our pipeline could prioritize putative causal genetic variants in major depression. More importantly, it can be applied when only index genetic variants are available. Finally, the presented approach enabled the proposal of mechanistic hypotheses of these genetic variants and their role in disease pathogenesis., IMI2-JU resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme 2014–2020 [GA: 676559 Elixir-Excelerate]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013–2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. AMR was supported by CONACYT-FORDECYT-PRONACES grant no. [11311], and Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México (PAPIIT-UNAM) grant nos. IA203021. JPG was supported by Instituto de Salud Carlos III-Fondo Social Europeo [FI18/00034]; Instituto de Salud Carlos III [MV20]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The DisGeNET knowledge platform for disease genomics: 2019 update

  • Piñero González, Janet, 1977-
  • Ramírez Anguita, Juan Manuel
  • Saüch Pitarch, Josep
  • Ronzano, Francesco
  • Centeno, Emilio
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
One of the most pressing challenges in genomic medicine is to understand the role played by genetic variation in health and disease. Thanks to the exploration of genomic variants at large scale, hundreds of thousands of disease-associated loci have been uncovered. However, the identification of variants of clinical relevance is a significant challenge that requires comprehensive interrogation of previous knowledge and linkage to new experimental results. To assist in this complex task, we created DisGeNET (http://www.disgenet.org/), a knowledge management platform integrating and standardizing data about disease associated genes and variants from multiple sources, including the scientific literature. DisGeNET covers the full spectrum of human diseases as well as normal and abnormal traits. The current release covers more than 24 000 diseases and traits, 17 000 genes and 117 000 genomic variants. The latest developments of DisGeNET include new sources of data, novel data attributes and prioritization metrics, a redesigned web interface and recently launched APIs. Thanks to the data standardization, the combination of expert curated information with data automatically mined from the scientific literature, and a suite of tools for accessing its publicly available data, DisGeNET is an interoperable resource supporting a variety of applications in genomic medicine and drug R&D., SCIII-FEDER [PI13/00082, PI17/00230, CPII16/00026]; IMI-JU resources of which are composed of financial contribution from the EU-FP7 [FP7/2007–2013] and EFPIA companies in kind contribution [116030 to TransQST, 777365 to eTRANSAFE], and the EU H2020 Programme 2014–2020 [676559 to Elixir-Excelerate]; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER (PRB2-ISCIII [PT13/0001/0023, of the PE I+D+i 2013–2016]). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. Funding for open access charge: Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genomic and proteomic biomarker landscape in clinical trials

  • Piñero González, Janet, 1977-
  • Rodriguez Fraga, Pablo S.
  • Valls-Margarit, Jordi
  • Ronzano, Francesco
  • Accuosto, Pablo
  • Lambea Jane, Ricard
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
The use of molecular biomarkers to support disease diagnosis, monitor its progression, and guide drug treatment has gained traction in the last decades. While only a dozen biomarkers have been approved for their exploitation in the clinic by the FDA, many more are evaluated in the context of translational research and clinical trials. Furthermore, the information on which biomarkers are measured, for which purpose, and in relation to which conditions are not readily accessible: biomarkers used in clinical studies available through resources such as ClinicalTrials.gov are described as free text, posing significant challenges in finding, analyzing, and processing them by both humans and machines. We present a text mining strategy to identify proteomic and genomic biomarkers used in clinical trials and classify them according to the methodologies by which they are measured. We find more than 3000 biomarkers used in the context of 2600 diseases. By analyzing this dataset, we uncover patterns of use of biomarkers across therapeutic areas over time, including the biomarker type and their specificity. These data are made available at the Clinical Biomarker App at https://www.disgenet.org/biomarkers/, a new portal that enables the exploration of biomarkers extracted from the clinical studies available at ClinicalTrials.gov and enriched with information from the scientific literature. The App features several metrics that assess the specificity of the biomarkers, facilitating their selection and prioritization. Overall, the Clinical Biomarker App is a valuable and timely resource about clinical biomarkers, to accelerate biomarker discovery, development, and application., This work was partially funded by IMI2-JU grants, resources which are composed of financial contributions from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA [GA: 116030 TransQST and GA: 777365 eTRANSAFE], and the EU H2020 Programme [GA: 871075 Elixir-CONVERGE and GA:964537 RISKHUNT3R, which is part of the ASPIS cluster]; Project 001-P-001647—Valorisation of EGA for Industry and Society funded by the European Regional Development Fund (ERDF) and Generalitat de Catalunya; Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519], and the Institute of Health Carlos III (project IMPaCT-Data, exp. IMP/00019), co-funded by the European Union, European Regional Development Fund (ERDF, “A way to make Europe”). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and ERDF (PRB2-ISCIII [PT13/0001/0023, of the PE I + D + i 2013-2016]). The MELIS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO [MDM-2014-0370]. This work reflects only the author’s view and that the IMI2-JU is not responsible for any use that may be made of the information it contains. The European Commission is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Embracing the dark side: computational approaches to unveil the functionality of genes lacking biological annotation in drug-induced liver injury

  • Souza, Terezinha
  • Panuwat, Trairatphisan
  • Piñero González, Janet, 1977-
  • Furlong, Laura I., 1971-
  • Saez-Rodriguez, Julio
  • Kleinjans, Jos C.
  • Jennen, Danyel
In toxicogenomics, functional annotation is an important step to gain additional insights into genes with aberrant expression that drive pathophysiological mechanisms. Nevertheless, there exists a gap on annotation of these genes which often hampers the interpretation of results and limits their applicability in translational medicine. In this study, we evaluated the coverage of functional annotations of differentially expressed genes (DEGs) induced by 10 selected compounds from the TG-GATEs database identified as high- or no-risk in causing drug-induced liver injury (most-DILI or no-DILI, respectively) using in vitro human data. Functional roles of DEGs not present in the most common biological annotation databases - termed "dark genes" - were unveiled via literature mining and via the identification of shared regulatory transcription factors or signaling pathways. Our results demonstrated that there were approximately 13% of dark genes induced by these compounds in vitro and we were able to obtain additional relevant information for up to 76% of those. Using interactome data from several sources, we have uncovered genes such as LRBA, and WDR26 as highly connected in the protein network that play roles in drug response. Genes such as MALAT1, H19, and MIR29C - whose links to hepatotoxicity have been confirmed - were identified as markers for the most-DILI group and appeared as top hits across all literature-based mining methods. Furthermore, we investigated the potential impact of dark genes on liver toxicity by identifying their rat orthologs in combination with their correlation to drug-induced liver pathologies observed in vivo following chemical exposure. We identified a set of important regulatory transcription factors of dark genes for all most-DILI compounds including E2F1 and JUND with supporting evidences in literature and we found Magee1 correlated with chemically induced bile duct hyperplasia and adverse responses at 29 days in rats in vivo. In conclusion, in this study we show the potential role of these poorly annotated genes in mechanisms underlying hepatotoxicity and offer a number of computational approaches that may help to minimize current gaps in gene annotation and highlight their values as potential biomarkers in toxicological studies., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 116030 (TransQST). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Network, transcriptomic and genomic features differentiate genes relevant for drug response

  • Piñero González, Janet, 1977-
  • Gonzalez-Perez, Abel
  • Guney, Emre
  • Aguirre Plans, Joaquim, 1993-
  • Sanz, Ferran
  • Oliva Miguel, Baldomero
  • Furlong, Laura I., 1971-
Understanding the mechanisms underlying drug therapeutic action and toxicity is crucial for the prevention and management of drug adverse reactions, and paves the way for a more efficient and rational drug design. The characterization of drug targets, drug metabolism proteins, and proteins associated to side effects according to their expression patterns, their tolerance to genomic variation and their role in cellular networks, is a necessary step in this direction. In this contribution, we hypothesize that different classes of proteins involved in the therapeutic effect of drugs and in their adverse effects have distinctive transcriptomics, genomics and network features. We explored the properties of these proteins within global and organ-specific interactomes, using multi-scale network features, evaluated their gene expression profiles in different organs and tissues, and assessed their tolerance to loss-of-function variants leveraging data from 60K subjects. We found that drug targets that mediate side effects are more central in cellular networks, more intolerant to loss-of-function variation, and show a wider breadth of tissue expression than targets not mediating side effects. In contrast, drug metabolizing enzymes and transporters are less central in the interactome, more tolerant to deleterious variants, and are more constrained in their tissue expression pattern. Our findings highlight distinctive features of proteins related to drug action, which could be applied to prioritize drugs with fewer probabilities of causing side effects., We received support from ISCIII-FEDER (PI13/00082, CP10/00524, and CPII16/00026), IMI-JU under grant agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE) resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution, and the EU H2020 Program 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and was supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370). AG-P was supported by a Ramón y Cajal contract (RYC-2013-14554). BO and JA-P were supported by MINECO grant BIO2014-57518-R.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GUILDify v2.0: a tool to identify molecular networks underlying human diseases, their comorbidities and their druggable targets

  • Aguirre Plans, Joaquim, 1993-
  • Piñero González, Janet, 1977-
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
  • Fernández Fuentes, Narcís
  • Oliva Miguel, Baldomero
  • Guney, Emre
The genetic basis of complex diseases involves alterations on multiple genes. Unraveling the interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 2014, we introduced GUILDify, a web server that searches for genes associated to diseases, finds novel disease genes applying various network-based prioritization algorithms and proposes candidate drugs. Here, we present GUILDify v2.0, a major update and improvement of the original method, where we have included protein interaction data for seven species and 22 human tissues and incorporated the disease-gene associations from DisGeNET. To infer potential disease relationships associated with multi-morbidities, we introduced a novel feature for estimating the genetic and functional overlap of two diseases using the top-ranking genes and the associated enrichment of biological functions and pathways (as defined by GO and Reactome). The analysis of this overlap helps to identify the mechanistic role of genes and protein-protein interactions in comorbidities. Finally, we provided an R package, guildifyR, to facilitate programmatic access to GUILDify v2.0 (http://sbi.upf.edu/guildify2)., The authors received support from the following:ISCIII–FEDER (PI13/00082, CP10/00524, CPII16/00026); IMI-JU under grants agreements no. 116030(TransQST) and no. 777365 (eTRANSAFE), re-sources of which are composed of financial contribu-tion from the EU-FP7 (FP7/2007- 2013) and EFPIAcompanies in kind contribution; the EU H2020Programme 2014–2020 under grant agreementsno. 634143 (MedBioinformatics) and no. 676559(Elixir-Excelerate); the Spanish Ministry of Economy(MINECO) (BIO2017-85329-R, RYC-2015-17519);and“Unidad de Excelencia María de Maeztu,”fundedby the Spanish Ministry of Economy (ref.: MDM-2014-0370). The Research Programme on BiomedicalInformatics is a member of the Spanish NationalBioinformatics Institute, PRB2-ISCIII, and is supportedby Grant PT13/0001/0023 of the PE I+D+i 2013-2016funded by ISCIII and FEDER
Docta Complutense
Publication Artículo científico (JournalArticle)

Validation of the Edited Tromsø Infant Faces Database (E-TIF): A study on differences in the processing of children's emotional expressions

  • Duque, Almudena
  • Picado, Gonzalo
  • Salgado, Gloria
  • Salgado, Alfonso
  • Palacios, Beatriz
  • Chaves Vélez, Covadonga
Images of emotional facial expressions are often used in emotion research, which has promoted the development of different databases. However, most of these standardized sets of images do not include images from infants under 2 years of age, which is relevant for psychology research, especially for perinatal psychology. The present study aims to validate the edited version of the Tromsø Infant Faces Database (E-TIF) in a large sample of participants. The original set of 119 pictures was edited. The pictures were cropped to remove nonrelevant information, fitted in an oval window, and converted to grayscale. Four hundred and eighty participants (72.9% women) took part in the study, rating the images on five dimensions: depicted emotion, clarity, intensity, valence, and genuineness. Valence scores were useful for discriminating between positive, negative, and neutral facial expressions. Results revealed that women were more accurate at recognizing emotions in children. Regarding parental status, parents, in comparison with nonparents, rated neutral expressions as more intense and genuine. They also rated sad, angry, disgusted, and fearful faces as less negative, and happy expressions as less positive. The editing and validation of the E-TIF database offers a useful tool for basic and experimental research in psychology